Skip to main content
OPDIVO QVANTIG® (nivolumab + hyaluronidase-nvhy) logo and OPDIVO® (nivolumab) logo.
    • Non-small cell lung cancer (NSCLC)
    • Advanced kidney cancer
    • Gastroesophageal cancer
    • Melanoma
    • Bladder cancer
    • Head and neck squamous cell cancer
    • Malignant pleural mesothelioma
    • Colorectal cancer (MSI-H/dMMR)
    • Liver cancer
    • Other OPDIVO Indications
About Treatment
Clinical trial results
About subcutaneous injection
How this treatment works
Getting treatment
Side effects
FAQs
Patient & Caregiver Support
Sign up for support
Patient stories
Patient resources
Caregiver resources
Glossary
Cost & Access
    • Non-small cell lung cancer (NSCLC)
    • Advanced kidney cancer
    • Gastroesophageal cancer
    • Melanoma
    • Bladder cancer
    • Head and neck squamous cell cancer
    • Malignant pleural mesothelioma
    • Colorectal cancer (MSI-H/dMMR)
    • Liver cancer
    • Other OPDIVO Indications

foot note heading

1506-US-2500363  08/25